EDINBURGH, Scotland , May 23, 2022 /PRNewswire/ -- TC Biopharm (Holdings) PLC ("TC Biopharm" or the "Company") (NASDAQ: TCBP) (NASDAQ: TCBPW), a clinical stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer treatment, today announced that Kuick Research has recognized the Company as a key player in the gamma-delta T cell therapy market. In April, Kuick Research released its " Gamma Delta T Cell Cancer Therapy Market and Clinical Trials Forecast 2028 " which focuses on the therapy, the companies in the sector, updates on the current drugs in research & development, and the size of the sector.

Digital Brands Group, Inc. ("DBG") (NASDAQ: DBGI), a curated collection of luxury lifestyle, digital-first brands, today announces its initial 2022 revenue guidance of $37.5 million to $42.5 million, an increase of 350% from 2021 revenue expectations. Additionally, the Company forecasts positive EBITDA for 2022, as it leverages its shared services platform

SGOCO Group (NASDAQ:SGOC) is a conglomerate with four primary businesses — virtual reality, energy saving technology, mortgage lending and real estate investment. Based in China, the multihyphenate company was thrust into the spotlight in July thanks to a two-session performance that saw SGOC stock soar 675%.

The launch sending SNOA stock up today covers two new dental products: OroGenix Oral Hygiene Rinse and Microdacyn Oral Care. These products are for use by professionals, as well as consumers in some cases.OroGenix Oral Hygiene Rinse is the second dental product by Sonoma Pharmaceuticals in the U.S. It was developed with the help of partner Gabriel Science. The new product is an oral hygiene rinse that uses Sonoma Pharmaceuticals’ Microcyn tech to clean teeth, gums, and the mouth.Microdacyn Oral Care isn’t coming to the U.S. and is instead launching in Switzerland. This product is designed to “combat oral and pharyngeal infections and inflammation, and reduce pain and coughing.”The Top 7 Stocks to Buy for Under $20 in AugustBruce Thornton, COO of Sonoma Pharmaceuticals, said this about the news boosting SNOA stock higher today.“We are pleased to bring the oral rinse to dental offices in the U.S., and for both professional and consumer use in Europe.